Revisiting Amantadine as A Treatment for Drug-Induced Movement Disorders

Symmetrel [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2009.

Wendel HA , Snyder M T , Pell S. Trial of amantadine in epidemic influenza. Clin Pharmacol Ther. 1966;7:38–43.

Bleidner WE , Harmon JB , Hewes WE , . Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965;150:484–490.

Davies WL , Grunert RR , Haff RF , . Antiviral activity of 1-adamantanamine (amantadine). Science. 1964;144:862–863.

Alves Galvão MG , Rocha Crispino Santos MA , Alves da Cunha AJ . Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev. 2014:CD002745.

Schwab RS , England AC Jr , Poskanzer DC , . Amantadine in the treatment of Parkinson's disease. JAMA. 1969;208:1168–1170.

Parkes JD , Calver DM , Zilkha KJ , . Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970;1:259–262.

Caroff SN , Campbell EC . Drug-induced extra-pyramidal syndromes: implications for contemporary practice. Psychiatr Clin North Am. 2016;39:391–411.

Carbon M , Kane JM , Leucht S , . Tardive dyskinesia risk with first- and second-generation antipsychotics in comparative randomized controlled trials: a meta-analysis. World Psychiatry. 2018;17: 330–340.

Martino D , Karnik V , Osland S , . Movement disorders associated with antipsychotic medication in people with schizophrenia: an overview of Cochrane reviews and meta-analysis. Can J Psychiatry. 2018;63:706743718777392.

Nguyen TT , Pariente A , Montastruc JL , . An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017;83:612–622.

Mentzel TQ , Lieverse R , Bloemen O , . High incidence and prevalence of drug-related movement disorders in young patients with psychotic disorders. J Clin Psychopharmacol. 2017;37:231–238.

Caroff SN , Davis VG , Miller DD , ; CATIE Investigators. Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. J Clin Psychiatry. 2011;72:295–303.

Kelly DL , Weiner E , Ball MP , . Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. J Psychopharmacol. 2009;23:436–441.

McEvoy J , Park T , Schilling T , . The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders. Curr Med Res Opin. 2019;35:1205–1214.

Ward KM , Citrome L. Antipsychotic-related movement disorders: drug-induced parkinsonism vs. tardive dyskinesia-key differences in pathophysiology and clinical management. Neurol Ther. 2018;7:233–248.

Gunne LM , Andrén PE . An animal model for coexisting tardive dyskinesia and tardive parkinsonism: a glutamate hypothesis for tardive dyskinesia. Clin Neuropharmacol. 1993;16:90–95.

Huang Y , Pan L , Teng F , . A cross-sectional study on the characteristics of tardive dyskinesia in patients with chronic schizophrenia. Shanghai Arch Psychiatry. 2017;29:295–303.

Caroff SN , Hurford I , Lybrand J , . Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial. Neurol Clin. 2011;29:127-148.

Greenblatt DJ , DiMascio A , Harmatz JS , . Pharmacokinetics and clinical effects of amantadine in drug-induced extrapyramidal symptoms. J Clin Pharmacol. 1977;17:704–708.

Pahwa R , Tanner CM , Hauser RA , . Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study). Mov Disord. 2015;30:788–795.

Aoki FY , Sitar DS . Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet. 1988;14:35-51.

Deleu D , Northway MG , Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41:261–309.

de Vries T , Dentiste A , Handiwala L , . Bioavailability and pharmacokinetics of once-daily amantadine extended-release tablets in healthy volunteers: results from three randomized, crossover, open-label, phase 1 studies. Neurol Ther. 2019;8: 449–460.

Hauser RA , Pahwa R , Wargin WA , . Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2019;58:77–88.

de Vries T , Dentiste A , Di Lea C , . Effects of renal impairment on the pharmacokinetics of once-daily amantadine extended-release tablets. CNS Drugs. 2019;33:783–789.

Creese I , Burt DR , Snyder SH . Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976;192:481–483.

Tauscher J , Küfferle B , Asenbaum S , . Striatal dopamine-2 receptor occupancy as measured with [123I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol. Psychopharmacology (Berl). 2002;162:42–49.

Stoof JC , Booij J , Drukarch B , . The anti-parkinsonian drug amantadine inhibits the N-methyl-d-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way. Eur J Pharmacol. 1992;213:439–443.

Conti MM , Chambers N , Bishop C. A new outlook on cholinergic interneurons in Parkinson's disease and L-DOPA-induced dyskinesia. Neurosci Biobehav Rev. 2018;92:67–82.

Cunningham Owens DG . A guide to the extrapyramidal side-effects of antipsychotic drugs. London, United Kingdom: Cambridge University Press; 2014.

Matsubayashi H , Swanson KL , Albuquerque EX . Amantadine inhibits nicotinic acetylcholine receptor function in hippocampal neurons. J Pharmacol Exp Ther. 1997;281:834–844.

Syvälahti EK , Kunelius R , Lauren L. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol. 1988;62:90–94.

Elmer LW , Juncos JL , Singer C , . Pooled analyses of phase III studies of ADS-5102 (amantadine) extended-release capsules for dyskinesia in Parkinson's disease. CNS Drugs. 2018;32:387–398.

Osmolex ER [package insert]. Basking Ridge, NJ: Osmotica Pharmaceutical; 2018.

Greenamyre JT , O'Brien C F . N-methyl-d-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol. 1991;48:977–981.

Kornhuber J , Bormann J , Hübers M , . Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol. 1991;206:297–300.

Kornhuber J , Weller M , Schoppmeyer K , . Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl. 1994;43:91–104.

Pacifici GM , Nardini M , Ferrari P , . Effect of amantadine on drug-induced parkisonism: relationship between plasma levels and effect. Br J Clin Pharmacol. 1976;3:883–889.

Desmarais JE , Beauclair L , Annable L , . Effects of discontinuing anticholinergic treatment on movement disorders, cognition and psychopathology in patients with schizophrenia. Ther Adv Psychopharmacol. 2014;4:257-267.

Wang Q , Zhang W. Maladaptive synaptic plasticity in L-DOPA-induced dyskinesia. Front Neural Circuits. 2016;10:105. doi:10.3389/fncir.2016.00105.

Andreassen OA , Aamo TO , Jøorgensen HA . Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br J Pharmacol. 1996;119:751–757.

Tarsy D. Neuroleptic-induced extrapyramidal reactions: classification, description, and diagnosis. Clin Neuropharmacol. 1983;6:(suppl 1)S9–S26.

Tarsy D , Simon DK . Dystonia. N Engl J Med. 2006;355:818–829.

Mazurek M , Rosebush P. Acute drug-induced dystonia. In: Factor SA , Lang AE , Weiner WJ , eds. Drug induced movement disorders, 2nd ed. Malder, MA: Blackewell Publishing, Inc.; 2005.

American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.

van Harten PN , Hoek HW , Kahn RS . Acute dystonia induced by drug treatment. BMJ. 1999;319:623–626.

Caroff SN , Rosenheck RA . Extrapyramidal side effects. In: Stroup TS , Lieberman JA , eds. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: how does it inform practice, policy, and research? Cambridge, United Kingdom: Cambridge University Press; 2010:156–172.

Park HW , Kwak JR , Lee JS . Clinical characteristics of acute drug-induced dystonia in pediatric patients. Clin Exp Emerg Med. 2017;4:133–137.

Thenganatt MA , Jankovic J. Treatment of dystonia. Neurotherapeutics. 2014;11:139–152.

Satterthwaite TD , Wolf DH , Rosenheck RA , . A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69: 1869–1879.

Merrick EM , Schmitt PP . A controlled study of the clinical effects of amantadine hydrochloride (Symmetrel). Curr Ther Res Clin Exp. 1973;15:552–558.

Hardie RJ , Lees AJ . Neuroleptic-induced Parkinson's syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51:850-854.

Misdrahi D , Tessier A , Daubigney A , ; FACE-SZ (FondaMental Academic Centers of Expertise for Schizphrenia) Group. Prevalence of and risk factors for extrapyramidal side effects of antipsychotics: results from the National FACE-SZ Cohort. J Clin Psychiatry. 2019;80:18m12246. doi: 10.4088/JCP.18m12246.

Morley J F , Pawlowski SM , Kesari A , . Motor and non-motor features of Parkinson's disease that predict persistent drug-induced parkinsonism. Parkinsonism Relat Disord. 2014;20:738–742.

Morley J F , Duda JE . Use of hyposmia and other non-motor symptoms to distinguish between drug-induced parkinsonism and Parkinson's disease. J Parkinsons Dis. 2014;4:169–173.

Caroff SN , Mann SC , Campbell EC , . Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry. 2002;63:(suppl 4)12–19.

Tarsy D , Baldessarini RJ , Tarazi FI . Effects of newer antipsychotics on extrapyramidal function. CNS Drugs. 2002;16:23–45.

Morley JF , Cheng G , Dubroff JG , . Olfactory impairment predicts underlying dopaminergic deficit in presumed drug-induced parkinsonism. Mov Disord Clin Pract. 2016;4:603–606.

Dayalu P , Chou KL . Antipsychotic-induced extra-pyramidal symptoms and their management. Expert Opin Pharmacother. 2008;9:1451–1462.

Friedman JH , Trieschmann ME , Fernandez HH . Drug-induced parkinsonism. In: Factor SA , Lang AE , Weiner WJ , eds. Drug induced movement disorders. 2nd ed. Malden, MA: Blackwell Publishing, Inc.; 2005:103–139.

Gelenberg AJ . Treating extrapyramidal reactions: some current issues. J Clin Psychiatry. 1987;48:(suppl)24–27.

Yaryura-Tobias JA , Wolpert A , Dana L , . Action of L-Dopa in drug induced extrapyramidalism. Dis Nerv Syst. 1970;31:60–63.

Vale S , Espejel MA . Amantadine for dyskinesia tarda. N Engl J Med. 1971;284:673.

Kelly J T , Abuzzahab FS Sr. The antiparkinson properties of amantadine in drug-induced parkinsonism. J Clin Pharmacol New Drugs. 1971;11:211–214.

Ananth J , Sangani H , Noonan JP . Amantadine in drug-induced extrapyramidal signs: a comparative study. Int J Clin Pharmacol Biopharm. 1975;11:323–326.

Kelly JT , Zimmermann RL , Abuzzahab FS , . A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. Pharmacology. 1974;12:65–73.

Stenson RL , Donion PT , Meyer JE . Comparison of benztropine mesylate and amantadine HCl in neuroleptic-induced extrapyramidal symptoms. Compr Psychiatry. 1976;17:763–768.

Fann WE , Lake CR . Amantadine versus trihexyphenidyl in the treatment of neuroleptic-induced parkinsonism. Am J Psychiatry. 1976;133:940–943.

Di Mascio A , Bernardo DL , Greenblatt DJ , . A controlled trial of amantadine in drug-induced extrapyramidal disorders. Arch Gen Psychiatry. 1976;33:599-602.

Borison RL . Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol. 1983;6:(suppl 1)S57–S63.

Konig P , Chwatal K , Havelec L , . Amantadine versus biperiden: a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology. 1996;33:80–84.

Silver H , Geraisy N , Schwartz M. No difference in the effect of biperiden and amantadine on parkinsonian-and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients. J Clin Psychiatry. 1995;56:167–170.

Mindham RH , Gaind R , Anstee BH , . Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced parkinsonism. Psychol Med. 1972;2:406–413.

McEvoy JP , McCue M , Freter S. Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia. Clin Ther. 1987;9:429–433.

Fayen M , Goldman MB , Moulthrop MA , . Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyramidal symptoms. Am J Psychiatry. 1988;145:483–486.

McEvoy JP . A double-blind crossover comparison of antiparkinson drug therapy: amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function. J Clin Psychiatry. 1987;48:(suppl)20–23.

Miller DD , McEvoy JP , Davis SM , . Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005;80:33–43.

Soares-Weiser K , Fernandez HH . Tardive dyskinesia. Semin Neurol. 2007;27:159–169.

van Harten PN , Hoek HW , Matroos GE , . The inter-relationships of tardive dyskinesia, parkin-sonism, akathisia and tardive dystonia: the Curacao Extrapyramidal Syndromes Study II. Schizophr Res. 1997;26:235–242.

Salem H , Nagpal C , Pigott T , . Revisiting antipsychotic-induced akathisia: current issues and prospective challenges. Curr Neuropharmacol. 2017;15: 789–798.

Peitl MV , Prološãić J , Blazevic-Zelic S , . Symptoms of agitated depression and/or akathisia. Psychiatr Danub. 2011;23:108–110.

Young SL , Taylor M , Lawrie SM . “First do no harm. ” A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015;29:353–362.

Kane JM , Fleischhacker WW , Hansen L , . Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiatry. 2009;70: 627–643.

Berna F , Misdrahi D , Boyer L , , FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Akathisia: prevalence and risk factors in a community-dwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophr Res. 2015;169:255–261.

Bratti IM , Kane JM , Marder SR . Chronic restlessness with antipsychotics. Am J Psychiatry. 2007;164: 1648–1654.

Forcen FE , Matsoukas K , Alici Y. Antipsychotic-induced akathisia in delirium: a systematic review. Palliat Support Care. 2016;14:77–84.

Rathbone J , Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2006:CD003727.

Adler LA , Rotrosen J , Angrist B. Acute drug-induced akathisia. In: Factor SA , Lang AE , Weiner WJ , eds. Drug induced movement disorders. 2nd ed. Malden, MA: Blackwell Publishing, Inc.; 2005:140–173.

Lima AR , Soares-Weiser K , Bacaltchuk J , . Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2002:CD001950.

Poyurovsky M , Weizman A. Treatment of anti-psychotic-related akathisia revisited: the role of serotonin 2a receptor antagonists. J Clin Psychopharmacol. 2015;35:711–714.

Zubenko GS , Barreira P , Lipinski JF Jr. Development of tolerance to the therapeutic effect of amantadine on akathisia. J Clin Psychopharmacol. 1984;4:218–220.

Zutshi D , Cloud LJ , Factor SA . Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: experience from a university-based movement disorder clinic. Tremor Other Hyperkinet Mov (N Y). 2014;4:266. doi: 10.7916/D8MS3R8C.

Carbon M , Hsieh CH , Kane JM , . Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis. J Clin Psychiatry. 2017; 78:e264–e278.

Halliday J , Farrington S , Macdonald S , . Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry. 2002;181:422–427.

Caroff SN . Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatr Dis Treat. 2019;15:785–794.

Bhidayasiri R , Jitkritsadakul O , Friedman JH , . Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm. J Neurol Sci. 2018;389: 67–75.

Fernandez HH , Factor SA , Hauser RA , . Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017; 88:2003–1010.

O'Brien CF , Jimenez R , Hauser RA , . NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687.

Austedo [package insert]. North Wales, PA: Teva Pharmaceuticals; 2017.

Ingrezza [package insert]. San Diego, CA: Neurocrine Biosciences, Inc.; 2017.

Freudenreich O , McEvoy JP . Added amantadine may diminish tardive dyskinesia in patients requiring continued neuroleptics. J Clin Psychiatry. 1995;56:173.

Decker BL , Davis JM , Jonowsky DS , . Amantadine hydrochloride treatment of tardive dyskinesia. N Engl J Med. 1971;285:860.

Crane GE . More on amantadine in tardive dyskinesia. N Engl J Med. 1971;285:1150–1151.

Dynes JB . Oral dyskinesias–occurrence and treatment. Dis Nerv Syst. 1970;31:854–859.

Janowsky DS , el-Yousef MK , Davis JM , . Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism. N Engl J Med. 1972;286:785.

Merren MD . Amantadine in tardive dyskinesia. N Engl J Med. 1972;286:268.

Allen RM . Role of amantadine in the management of neuroleptic-induced extrapyramidal syndromes: overview and pharmacology. Clin Neuropharmacol. 1983;6:(suppl 1)S64–S73.

Borison RL , Diamond BI . Anticholinergics promote neuroleptic-induced tardive dyskinesia. Adv Biochem Psychopharmacol. 1980;24:359–361.

Carvey PM , Kao LC , Zhang TJ , . Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity. Pharmacol Biochem Behav. 1990;35:291–300.

Angus S , Sugars J , Boltezar R , . A controlled trial of amantadine hydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol. 1997;17:88–91.

Pappa S , Tsouli S , Apostolou G , . Effects of amantadine on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Clin Neuropharmacol. 2010;33:271–275.

Dashtipour K , Tafreshi AR , Pahwa R , . Extended-release amantadine for levodopa-induced dyskinesia. Expert Rev Neurother. 2019;19:293–299.

Raupp-Barcaro I F , Vital MA , Galduroz JC , . Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials. Braz J Psychiatry. 2018;40:449–458.

Gelenberg AJ , Mandel MR . Catatonic reactions to high-potency neuroleptic drugs. Arch Gen Psychiatry. 1977;34:947–950.

Lopez-Canino A , Francis A. Drug-induced catatonia. In: Caroff SN , Mann SC , Francis A , , eds. Catatonia: from psychopathology to neurobiology. Washington, DC: American Psychiatric Press, Inc.; 2004: 129–139

Wijemanne S , Jankovic J. Movement disorders in catatonia. J Neurol Neurosurg Psychiatry. 2015;86:825-832.

Fricchione G , Mann SC , Caroff SN . Catatonia, lethal catatonia and neuroleptic malignant syndrome. Psychiatr Ann. 2000;30:347–355.

Stübner S , Rustenbeck E , Grohmann R , . Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry. 2004; 37(suppl 1):S54–S64.

Caroff SN , Hurford I , Bleier HR , . Recurrent Idiopathic Catatonia: implications beyond the Diagnostic and Statistical Manual of Mental Disorders 5th Edition. Clin Psychopharmacol Neurosci. 2015;13:218–221.

Mann SC , Caroff SN , Bleier HR , . Lethal catatonia. Am J Psychiatry. 1986;143:1374–1381.

Van Den Eede F , van Hecke J , van Dalfsen A , . The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry. 2005;20:422–429.

Peralta V , Campos MS , de Jalon EG , . DSM-IV catatonia signs and criteria in first-episode, drug-naive, psychotic patients: psychometric validity and response to antipsychotic medication. Schizophr Res. 2010;118:168–175.

Brenner I , Rheuban WJ . The catatonic dilemma. Am J Psychiatry. 1978;135:1242–1243.

Beach SR , Gomez-Bernal F , Huffman JC , . Alternative treatment strategies for catatonia: a systematic review. Gen Hosp Psychiatry. 2017;48:1–19.

Carroll BT , Thomas C , Jayanti K. Amantadine and memantine in catatonic schizophrenia. Ann Clin Psychiatry. 2006;18:133–134.

Theibert HPM , Carroll BT . NMDA antagonists in the treatment of catatonia: a review of case studies from the last 10 years. Gen Hosp Psychiatry. 2018;51:132–133.

Simon P , Malatray J , Boissier JR . Antagonism by amantadine of prochlorpemazine-induced catalepsy. J Pharm Pharmacol. 1970;22:546–547.

Caroff SN . The neuroleptic malignant syndrome. J Clin Psychiatry. 1980;41:79–83.

Gurrera RJ , Caroff SN , Cohen A , . An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry. 2011;72:1222–1228.

Caroff SN , Mann SC . Neuroleptic malignant syndrome. Med Clin North Am. 1993;77:185–202.

Spivak B , Maline DI , Kozyrev VN , . Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow. Eur Psychiatry. 2000;15:330–333.

Weller M , Kornhuber J. A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. Med Hypotheses. 1992;38:329–333.

Sakkas P , Davis JM , Janicak PG , . Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27:381–384.

Fryml LD , Williams KR , Pelic CG , . The role of amantadine withdrawal in 3 cases of treatment-refractory altered mental status. J Psychiatr Pract. 2017; 23:191–199.